hiSG Sleep Health Study (hiSG-SHS)

Evaluation of Goal-Based Interventions to Promote and Sustain Healthy Sleep Habits

The hiSG Sleep Health Study seeks to investigate the efficacy of education + goal-based programmes for the promotion of healthy sleep habits and to evaluate its impact on daytime sleepiness and mental health.

Study Overview

• Status: Completed
• Conditions: Sleep
• Intervention / Treatment: Device: Fitbit; Behavioral: Sleep education tips; Behavioral: Goal-setting

Detailed Description

This study is a sub-study under the existing Health Insights Singapore study (hiSG). The hiSG study is a longitudinal cohort study among working adults (aged 21-42y), monitoring health parameters through a Fitbit tracker and mobile phone-based questionnaires.

The hiSG Sleep Health Study (hiSG SHS) sub-study, will evaluate the efficacy of two goal-based interventions for improving sleep. Participants will be recruited from the existing hiSG subject pool (target N=300), and should have a habitual sleep duration below the recommended 7h (as determined from the currently available hiSG data). Following informed consent, participants will be randomized by the study team into two groups, a) Goal-Setting and b) Tracking, based on a 2:1 ratio, i.e. in the event 300 participants are enrolled, 200 will be allocated to Goal-Setting and 100 to Tracking.

The study is 22 weeks long and will proceed in 3 main phases, namely, 1) Baseline (Week 1-2) 2) Intervention (Week 3-12), and 3) Follow-up (Week 13-22).

Throughout the study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.

Daily questionnaires probing daytime sleepiness, mood, and stress levels as well as once-per-study phase sleep health, sleep hygiene, work-related stress and mental wellbeing questionnaires will be pushed to participants during the baseline (Week 1-2), intervention (Week 11-12) and follow-up periods (Week 21-22) via the hiSG mobile application. Participants will also be reimbursed for completion of these questionnaires.

Both groups will also receive sleep education tips before the intervention period. During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.

In addition, given the pervasive telecommuting arrangements presently enforced in many workplaces to curb spread of the COVID-19 pandemic, a work-life balance, burnout and work engagement questionnaire will be administered to better understand reasons that could contribute to poor sleep health and mental wellbeing.

• Study Type: Interventional
• Enrollment (Actual): 225
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Singapore
  • Singapore, Singapore
    • Centre for Sleep and Cognition

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 42 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Existing participants in the hiSG study
• Aged 21-42y
• Sleep <7h habitually on weekdays

Exclusion Criteria:

• Shift workers
• Those required to work in different time zones
• Currently Pregnant
• Nursing mothers

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Tracking; Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.	Device: Fitbit; A consumer sleep tracker will be used to monitor sleep patterns throughout the study; Behavioral: Sleep education tips; Sleep tips will be provided before the intervention phase
Experimental: Goal-Setting; Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week. During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.	Device: Fitbit; A consumer sleep tracker will be used to monitor sleep patterns throughout the study; Behavioral: Sleep education tips; Sleep tips will be provided before the intervention phase; Behavioral: Goal-setting; During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in sleep duration measured by wearable device (mins)	We hypothesize that the Goal-Setting group will exhibit longer sleep duration across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in sleep duration regularity (standard deviation) measured by wearable device (mins)	We hypothesize that the Goal-Setting group will exhibit more consistent sleep durations across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in bedtimes measured by wearable device	We hypothesize that the Goal-Setting group will exhibit earlier bedtimes across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in bedtime regularity (standard deviation) measured by wearable device	We hypothesize that the Goal-Setting group will exhibit more consistent bedtimes across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in social jetlag (midpoint of sleep on weekends - weekdays) measured by wearable device	We hypothesize that the Goal-Setting group will exhibit reduced social jetlag measures across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in scores on the Sleep Health Index questionnaire	We hypothesize that the Goal-Setting group will exhibit improved sleep health across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in scores on the Sleep Hygiene Scale questionnaire	We hypothesize that the Goal-Setting group will exhibit better sleep hygiene across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in scores on the Work-Related Perseverative Thought and Work Home Interference questionnaires	We hypothesize that the Goal-Setting group will exhibit reduced work stress levels across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)
Change in scores on the Oldenberg Burnout Inventory questionnaire	We hypothesize that the Goal-Setting group will exhibit reduced burnout across both Intervention and Follow-Up phases, compared to the Tracking group.	Baseline (Week 1-2), Intervention (Week 11-12), Follow up (Week 21-22)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bi-directional relationships between amount of nocturnal sleep obtained and daytime sleepiness levels.	We hypothesize that longer sleep duration will be associated with improved next day sleepiness [0-100 scale]	Day-by-day associations (Week 1-2, Week 11-12, Week 21-22)
Bi-directional relationships between amount of nocturnal sleep obtained and daytime mood and stress levels.	We hypothesize that longer sleep duration will be associated with improved next day stress levels [0-100 scale]	Day-by-day associations (Week 1-2, Week 11-12, Week 21-22)
Bi-directional relationships between amount of nocturnal sleep obtained and daytime motivational levels.	We hypothesize that longer sleep duration will be associated with improved next day motivational levels [0-100 scale]	Day-by-day associations (Week 1-2, Week 11-12, Week 21-22)
Bi-directional relationships between amount of nocturnal sleep obtained and daytime mood levels.	We hypothesize that longer sleep duration will be associated with improved next day mood levels [0-100 scale]	Day-by-day associations (Week 1-2, Week 11-12, Week 21-22)
Associations between Oldenberg Burnout Inventory, Work-Related Perseverative Thought and Work Home Interference with poorer Sleep Health Index scores.	We also hypothesize that individuals who score poorly on these burnout scales will also exhibit poorer sleep health scores.	Average scores (Week 1-2)

Collaborators and Investigators

• Sponsor: National University, Singapore
• Collaborators: Health Promotion Board, Singapore

Study record dates

Study Major Dates

• Study Start (Actual): August 15, 2021
• Primary Completion (Actual): January 16, 2022
• Study Completion (Actual): August 16, 2022

Study Registration Dates

• First Submitted: April 27, 2021
• First Submitted That Met QC Criteria: May 5, 2021
• First Posted (Actual): May 7, 2021

Study Record Updates

• Last Update Posted (Actual): January 18, 2023
• Last Update Submitted That Met QC Criteria: January 13, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: hiSG-SHS

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No